Nothing said here yet.
to join the conversation.
| Krempa DavidChief Business Officer | Sell | 4,166 | $229.4K | Tue, Oct 6 |
| MAIER PAUL VDirector | Sell | 36,387 | $2.1M | Fri, Aug 28 |
| MAIER PAUL VDirector | Sell | 13,485 | $811.9K | Fri, Aug 28 |
| MAIER PAUL VDirector | Sell | 128 | $7.9K | Fri, Aug 28 |
| Krempa DavidChief Business Officer | Sell | 25,000 | $1.6M | Mon, Aug 24 |
| BRYNJELSEN SEANPresident & CEO | Sell | 47,307 | $2.8M | Thu, Aug 20 |
| BRYNJELSEN SEANPresident & CEO | Sell | 36,373 | $2.2M | Thu, Aug 20 |
| BRYNJELSEN SEANPresident & CEO | Sell | 7,342 | $456.1K | Thu, Aug 20 |
| BRYNJELSEN SEANPresident & CEO | Sell | 8,978 | $562.5K | Wed, Aug 19 |
Eton Pharmaceuticals has delivered a very large 3 year gain for shareholders, which naturally raises the question of whether the current share price still lines up with what its earnings can support.
Eton's sales surge, raised 2026 outlook and expanding rare-disease portfolio are boosting confidence in its growth.
During the lightning round of the August 26 Mad Money episode, a caller asked whether it is time to “cut it off” or if Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has more potential given that they bought the shares at $30 and the stock is now above $60.
DEER PARK, Ill., Aug.
Revenue surged 99% year-over-year on HEMANGEOL relaunch and rare disease portfolio growth.
Eton Pharmaceuticals (ETON) has become a focus for investors after its second quarter 2026 report, which showed US$37.59 million in revenue, US$11.58 million in net income, and a shift from loss to earnings per share.
Eton's cure for an expensive valuation: a 99% sales growth rate.
Eton expects full-year 2026 revenue to exceed $145 million, up from its previous forecast of more than $120 million.